Robert Charles Blaylock

US Patent:

20110294737, Dec 1, 2011

Filed:

Oct 7, 2009

Appl. No.:

13/122886

Inventors:

Hansjorg Schwertz - Salt Lake City UT, US
Robert C. Blaylock - Salt Lake City UT, US
Larry W. Kraiss - Salt Lake City UT, US
Guy A. Zimmerman - Salt Lake City UT, US
Andrew S. Weyrich - Salt Lake City UT, US

International Classification:

A61K 38/02
A61K 31/7072
A61K 31/551
A61K 31/496
A61K 31/536
A61P 7/00
A61K 31/203
A61K 31/708
A61K 31/7068
A61K 31/513
A61K 31/52
C12N 5/078
A61K 31/505

US Classification:

514 135, 435325, 435391, 514 50, 514220, 51425309, 5142305, 514272, 514559, 514 45, 514 49, 514274, 5142634

Abstract:

Platelets are induced to proliferate, form extensions and produce daughter cells by various methods, including culturing platelets under thrombocytopenic conditions. Expansion of platelet cell numbers increases the storage life of platelets. Modulation of RT activity can be used to produce new daughter platelets. Therefore, the invention provides a new therapeutic use for RT inhibitors that can now be used for treatment of thrombocytopenia and related disorders. Likewise, application of soluble protein factor that may be secreted and/or released by platelets cultured under thrombocytopenic conditions may also be used as a therapeutic agent to increase platelet numbers.